Emerging complexity and the need for advanced drug delivery in targeting Candida species

Wadhwa, R; Pandey, P; Gupta, G; Aggarwal, T; Kumar, N; Mehta, M; Satija, S; Gulati, M; Madan, J; Dureja, H; Balusamy, SR; Perumalsamy, H; Maurya, PK; Collet, T; Tambuwala, MM; Hansbro, PM; Chellappan, DK; Dua, K

Emerging complexity and the need for advanced drug delivery in targeting Candida species

Wadhwa, R Pandey, P Gupta, G Aggarwal, T Kumar, N Mehta, M Satija, S Gulati, M Madan, J Dureja, H Balusamy, SR Perumalsamy, H Maurya, PK Collet, T Tambuwala, MM Hansbro, PM

Chellappan, DK Dua, K

Permalink

Publication Type:: Journal Article
Citation:: Current Topics in Medicinal Chemistry, 2019, 19 (28), pp. 2593 - 2609
Issue Date:: 2019-01-01

Closed Access

	Filename	Description	Size
	Emerging Complexity and the Need for Advanced Drug Delivery in Targeting.pdf	Accepted Manuscript Version	1.01 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Wadhwa, R	en_US
dc.contributor.author	Pandey, P	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Aggarwal, T	en_US
dc.contributor.author	Kumar, N	en_US
dc.contributor.author	Mehta, M	en_US
dc.contributor.author	Satija, S	en_US
dc.contributor.author	Gulati, M	en_US
dc.contributor.author	Madan, J	en_US
dc.contributor.author	Dureja, H	en_US
dc.contributor.author	Balusamy, SR	en_US
dc.contributor.author	Perumalsamy, H	en_US
dc.contributor.author	Maurya, PK	en_US
dc.contributor.author	Collet, T	en_US
dc.contributor.author	Tambuwala, MM	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Chellappan, DK	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.date.available	2019-09-07	en_US
dc.date.issued	2019-01-01	en_US
dc.identifier.citation	Current Topics in Medicinal Chemistry, 2019, 19 (28), pp. 2593 - 2609	en_US
dc.identifier.issn	1568-0266	en_US
dc.identifier.uri	http://hdl.handle.net/10453/137691
dc.description.abstract	© 2019 Bentham Science Publishers. Background: Candida species are the important etiologic agents for candidiasis, the most prevalent cause of opportunistic fungal infections. Candida invasion results in mucosal to systemic infections through immune dysfunction and helps in further invasion and proliferation at several sites in the host. The host defence system utilizes a wide array of the cells, proteins and chemical signals that are distributed in blood and tissues which further constitute the innate and adaptive immune system. The lack of antifungal agents and their limited therapeutic effects have led to high mortality and morbidity related to such infections. Methods: The necessary information collated on this review has been gathered from various literature published from 1995 to 2019. Results: This article sheds light on novel drug delivery approaches to target the immunological axis for several Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. rugose, C. hemulonii, etc.). Conclusion: It is clear that the novel drug delivery approaches include vaccines, adoptive transfer of primed immune cells, recombinant cytokines, therapeutic antibodies, and nanoparticles, which have immunomodulatory effects. Such advancements in targeting various underpinning mechanisms using the concept of novel drug delivery will provide a new dimension to the fungal infection clinic particularly due to Candida species with improved patient compliance and lesser side effects. This advancement in knowledge can also be extended to target various other similar microbial species and infections.	en_US
dc.relation.ispartof	Current Topics in Medicinal Chemistry	en_US
dc.relation.isbasedon	10.2174/1568026619666191026105308	en_US
dc.subject.classification	Medicinal & Biomolecular Chemistry	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Candida	en_US
dc.subject.mesh	Candidiasis	en_US
dc.subject.mesh	Antifungal Agents	en_US
dc.subject.mesh	Drug Delivery Systems	en_US
dc.subject.mesh	Microbial Sensitivity Tests	en_US
dc.subject.mesh	Species Specificity	en_US
dc.title	Emerging complexity and the need for advanced drug delivery in targeting Candida species	en_US
dc.type	Journal Article
utslib.citation.volume	28	en_US
utslib.citation.volume	19	en_US
utslib.for	0304 Medicinal and Biomolecular Chemistry	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.issue	28	en_US
pubs.publication-status	Published	en_US
pubs.volume	19	en_US

Abstract:

© 2019 Bentham Science Publishers. Background: Candida species are the important etiologic agents for candidiasis, the most prevalent cause of opportunistic fungal infections. Candida invasion results in mucosal to systemic infections through immune dysfunction and helps in further invasion and proliferation at several sites in the host. The host defence system utilizes a wide array of the cells, proteins and chemical signals that are distributed in blood and tissues which further constitute the innate and adaptive immune system. The lack of antifungal agents and their limited therapeutic effects have led to high mortality and morbidity related to such infections. Methods: The necessary information collated on this review has been gathered from various literature published from 1995 to 2019. Results: This article sheds light on novel drug delivery approaches to target the immunological axis for several Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. rugose, C. hemulonii, etc.). Conclusion: It is clear that the novel drug delivery approaches include vaccines, adoptive transfer of primed immune cells, recombinant cytokines, therapeutic antibodies, and nanoparticles, which have immunomodulatory effects. Such advancements in targeting various underpinning mechanisms using the concept of novel drug delivery will provide a new dimension to the fungal infection clinic particularly due to Candida species with improved patient compliance and lesser side effects. This advancement in knowledge can also be extended to target various other similar microbial species and infections.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/137691